COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome.


Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
12 2021
Historique:
pubmed: 19 8 2021
medline: 21 12 2021
entrez: 18 8 2021
Statut: ppublish

Résumé

This national Israeli multicenter retrospective study aimed to characterize the clinical course of COVID-19 infection among patients with hematological malignancies, with special emphasis on treatment efficacy and outcome. Clinical and laboratory data from haemato-oncological patients diagnosed with COVID-19 from 16 medical centers were centrally reported. Multivariate regression analyses were used to determine variables associated with severe disease, hospitalization, and mortality. In total, 313 patients were included: 103 (35.7%) developed severe/critical respiratory infection, 178 (61.4%) were hospitalized, and 60 (20.0%) died. Age > 70 years was associated with severe/critical disease (

Identifiants

pubmed: 34405767
doi: 10.1080/10428194.2021.1966782
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

3384-3393

Auteurs

Ilana Levy (I)

Hematology Unit, Bnai Zion Medical Center, Haifa, Israel.
Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.

Avital Lavi (A)

Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.

Eran Zimran (E)

Hematology Department, Hadassah Hospital, Jerusalem, Israel.
Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Sigal Grisariu (S)

Hematology Department, Hadassah Hospital, Jerusalem, Israel.
Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Shlomzion Aumann (S)

Hematology Department, Hadassah Hospital, Jerusalem, Israel.
Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

Gilad Itchaki (G)

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Tamar Berger (T)

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Pia Raanani (P)

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Reut Harel (R)

Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.
Hematology Unit, HaEmek Medical Center, Afula, Israel.

Ariel Aviv (A)

Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.
Hematology Unit, HaEmek Medical Center, Afula, Israel.

Noa Lavi (N)

Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.
Hematology Institute, Rambam Medical Center, Haifa, Israel.

Tsila Zuckerman (T)

Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.
Hematology Institute, Rambam Medical Center, Haifa, Israel.

Lev Shvidel (L)

Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Hematology Unit, Kaplan Medical Center, Rehovot, Israel.

Osnat Jarchowsky (O)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hematology Department, Meir Medical Center, Kfar Saba, Israel.

Martin Ellis (M)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hematology Department, Meir Medical Center, Kfar Saba, Israel.

Katrin Herzog Tzarfati (K)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hematology Department, Shamir Medical Center, Zerifin, Israel.

Maya Koren-Michowitz (M)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hematology Department, Shamir Medical Center, Zerifin, Israel.

Yehonatan Sherf (Y)

Hematology Department, Soroka Medical Center, Beer-Sheva, Israel.
Faculty of Medicine, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Itai Levi (I)

Hematology Department, Soroka Medical Center, Beer-Sheva, Israel.
Faculty of Medicine, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Orit Sofer (O)

Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.
Hematology Unit, Hillel Yaffe Medical Center, Hadera, Israel.

Ofer Shpilberg (O)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hematology Unit, Assuta Ramat Hahayal Medical Center, Tel Aviv, Israel.

Nagib Dally (N)

Hematology Unit, Ziv Medical Center, Safed, Israel.
Faculty of Medicine, Bar Ilan Unifersity, Safed, Israel.

Celia Suriu (C)

Faculty of Medicine, Bar Ilan Unifersity, Safed, Israel.
Hematology Institute, Western Galilee Hospital, Nahariya, Israel.

Andrei Braester (A)

Faculty of Medicine, Bar Ilan Unifersity, Safed, Israel.
Hematology Institute, Western Galilee Hospital, Nahariya, Israel.

Sharon Ben Barouch (S)

Faculty of Medicine, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Hematology Unit, Assuta Ashdod Medical Center, Ashdod, Israel.

Merav Leiba (M)

Faculty of Medicine, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Hematology Unit, Assuta Ashdod Medical Center, Ashdod, Israel.

Daniela Goldstein (D)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hematology Unit, Wolfson Medical Center, Holon, Israel.

Nadav Sarid (N)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Hematology Unit, Wolfson Medical Center, Holon, Israel.

Shay Yeganeh (S)

Faculty of Medicine, Bar Ilan Unifersity, Safed, Israel.
Hematology Unit, Baruch Padeh Medical Center, Poriyah, Israel.

Jabour Halloun (J)

Hematology Unit, Bnai Zion Medical Center, Haifa, Israel.

Moshe Mittelman (M)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Internal Medicine A Department, Sourasky Medical Center, Tel Aviv, Israel.

Tamar Tadmor (T)

Hematology Unit, Bnai Zion Medical Center, Haifa, Israel.
Faculty of Medicine, Technion- Israel Institute of Technology, Haifa, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH